These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 10155317)
21. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace. Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999 [TBL] [Abstract][Full Text] [Related]
22. Drug therapy: safety, effectiveness, and economics. Brandys J Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340 [TBL] [Abstract][Full Text] [Related]
23. [Pharmacoeconomics in cardiovascular disease. Part 1: pharmacoeconomics in coronary heart disease]. Wozakowska-Kapłon B; Kempkiewicz T Pol Arch Med Wewn; 2003 Nov; 110(5):1367-73. PubMed ID: 16737009 [No Abstract] [Full Text] [Related]
24. [Pharmacoeconomics in cardiovascular disease. Part 2: pharmacoeconomics in congestive heart failure and arterial hypertension]. Wozakowska-Kapłon B; Kempkiewicz T Pol Arch Med Wewn; 2003 Nov; 110(5):1375-8. PubMed ID: 16737010 [No Abstract] [Full Text] [Related]
25. Drug therapy often cost-effective. Arkinstall WW CMAJ; 1996 Sep; 155(5):512. PubMed ID: 8804254 [No Abstract] [Full Text] [Related]
26. The pharmacoeconomics of high-cost biotechnology products. Dana WJ; Farthing K Pharm Pract Manag Q; 1998 Jul; 18(2):23-31. PubMed ID: 10185236 [TBL] [Abstract][Full Text] [Related]
27. Pharmacoeconomics of Biologic Therapy. Bukstein DA; Luskin AT Immunol Allergy Clin North Am; 2017 May; 37(2):413-430. PubMed ID: 28366485 [TBL] [Abstract][Full Text] [Related]
29. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Omnes LF; Bousquet J; Scheinmann P; Neukirch F; Jasso-Mosqueda G; Chicoye A; Champion L; Fadel R Eur Ann Allergy Clin Immunol; 2007 May; 39(5):148-56. PubMed ID: 17626329 [TBL] [Abstract][Full Text] [Related]
30. Pharmacoeconomics. Ahuja J; Gupta M; Gupta AK; Kohli K Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600 [TBL] [Abstract][Full Text] [Related]
31. Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives. Trippoli S Eur J Intern Med; 2017 Sep; 43():e36. PubMed ID: 28552463 [No Abstract] [Full Text] [Related]
32. [Pharmacoeconomics in contemporary medicine]. Czech M Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007 [TBL] [Abstract][Full Text] [Related]
34. New drugs and clinical economics: analysis of cost effectiveness in the assessment of pharmaceutical innovations. Eisenberg JM Rev Infect Dis; 1984; 6 Suppl 4():S905-8. PubMed ID: 6441225 [TBL] [Abstract][Full Text] [Related]
35. [Pharmacoeconomics of asthma]. Jahnz-Rózyk K; Targowski T Pol Merkur Lekarski; 2004 May; 16 Suppl 1():48-9. PubMed ID: 15524016 [TBL] [Abstract][Full Text] [Related]
36. [Pharmacoeconomics. A new concept of an old practice]. Palma-Aguirre JA Gac Med Mex; 1998; 134(5):621-4. PubMed ID: 9842147 [No Abstract] [Full Text] [Related]
37. Pharmacoeconomics: is a drug worth its cost? Marwick C JAMA; 1994 Nov; 272(18):1395. PubMed ID: 7933406 [No Abstract] [Full Text] [Related]
39. Pharmacoeconomics in Ireland. Concepts and terminology. Barry M; Feely J Ir J Med Sci; 2000; 169(1):63-4. PubMed ID: 10846864 [No Abstract] [Full Text] [Related]
40. Pharmacoeconomics and the formulary decision-making process. Bakst A Hosp Formul; 1995 Jan; 30(1):42-50. PubMed ID: 10172201 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]